S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:BGNE

BeiGene (BGNE) News Headlines

$194.47
+3.39 (+1.77%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$183.82
$199.16
50-Day Range
$130.30
$194.48
52-Week Range
$118.18
$426.56
Volume
225,669 shs
Average Volume
251,293 shs
Market Capitalization
$20.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$300.33
Get BeiGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

BGNE Media Mentions By Week

BGNE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BGNE
News Sentiment

-0.06

0.34

Average
Medical
News Sentiment

BGNE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BGNE Articles
This Week

10

6

BGNE Articles
Average Week



SourceHeadline
marketbeat.com logoBeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
marketbeat.com - August 3 at 3:26 AM
MarketBeat logoAnalysts Set BeiGene, Ltd. (NASDAQ:BGNE) Target Price at $300.33
americanbankingnews.com - August 6 at 3:32 AM
seekingalpha.com logoU.S.-listed shares of BeiGene rise after Q2 revenue more than doubles Y/Y
seekingalpha.com - August 5 at 8:43 AM
benzinga.com logoRecap: BeiGene Q2 Earnings - Benzinga
benzinga.com - August 4 at 3:55 PM
seekingalpha.com logoBeiGene GAAP EPADS of -$5.56 misses by $1.45, revenue of $341.57M beats by $30.5M - Seeking Alpha
seekingalpha.com - August 4 at 10:54 AM
businesswire.com logoBeiGene Reports Second Quarter 2022 Financial Results - Business Wire
businesswire.com - August 4 at 10:54 AM
finance.yahoo.com logoBeiGene Reports Second Quarter 2022 Financial Results
finance.yahoo.com - August 4 at 10:54 AM
finance.yahoo.com logoWhy BeiGene (BGNE) Might Surprise This Earnings Season
finance.yahoo.com - August 3 at 2:41 PM
MarketBeat logoBeiGene (NASDAQ:BGNE) Shares Gap Down to $168.08
americanbankingnews.com - August 3 at 5:40 AM
MarketBeat logoResearch Analysts Offer Predictions for BeiGene, Ltd.'s Q2 2022 Earnings (NASDAQ:BGNE)
americanbankingnews.com - July 30 at 1:16 AM
nypost.com logoJack Ma's Alibaba among hundreds of Chinese firms facing delisting - New York Post
nypost.com - July 29 at 6:48 PM
bloomberg.com logoAbbVie Slides After Cutting Sales Outlook on Cancer Drug Decline - Bloomberg
bloomberg.com - July 29 at 1:46 PM
nasdaq.com logoWhat's in the Cards for Sesen Bio's (SESN) Q2 Earnings? - Nasdaq
nasdaq.com - July 27 at 7:39 PM
MarketBeat logoBeiGene (NASDAQ:BGNE) PT Lowered to $293.00
americanbankingnews.com - July 18 at 3:52 AM
MarketBeat logoBeiGene (NASDAQ:BGNE) Stock Price Down 4.3%
americanbankingnews.com - July 15 at 7:48 AM
finance.yahoo.com logoBeigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
finance.yahoo.com - July 14 at 7:07 PM
seekingalpha.com logoFDA defers action on Novartis/BeiGene tislelizumab for esophagus cancer citing inspection - Seeking Alpha
seekingalpha.com - July 14 at 2:06 PM
marketwatch.com logoBeigene Says FDA Defers Action on BLA Due to Covid Travel Restrictions - MarketWatch
marketwatch.com - July 14 at 2:06 PM
finance.yahoo.com logoAbsci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires - Yahoo Finance
finance.yahoo.com - July 14 at 9:06 AM
businesswire.com logoBeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC - Business Wire
businesswire.com - July 14 at 9:06 AM
finance.yahoo.com logoBeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
finance.yahoo.com - July 14 at 9:06 AM
businesswire.com logoBeiGene Appoints Chan Lee as General Counsel - Business Wire
businesswire.com - July 13 at 8:41 PM
finance.yahoo.com logoBeiGene Appoints Chan Lee as General Counsel
finance.yahoo.com - July 13 at 10:41 AM
finance.yahoo.com logoIs BeiGene (BGNE) a Smart Long-Term Investment?
finance.yahoo.com - July 12 at 8:08 PM
streetinsider.com logoLeap Therapeutics (LPTX) and BeiGene (BGNE) Initiate New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer - StreetInsider.com
streetinsider.com - July 12 at 8:02 AM
finance.yahoo.com logoLeap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
finance.yahoo.com - July 12 at 8:02 AM
marketwatch.com logoADRs End Lower; BeiGene, JinkoSolar Trade Actively - MarketWatch
marketwatch.com - July 6 at 10:46 PM
seekingalpha.com logoBeiGene in pact with InnoRNA to develop messenger RNA-based therapies (NASDAQ:BGNE) - Seeking Alpha
seekingalpha.com - July 6 at 10:46 PM
businesswire.com logoBeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Business Wire
businesswire.com - July 6 at 9:04 AM
seekingalpha.com logoWith just 16 new drugs approved in H1 2022, FDA poised for slew of approvals in H2 (BMY) - Seeking Alpha
seekingalpha.com - July 3 at 6:12 PM
finance.yahoo.com logoMyeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D. - Yahoo Finance
finance.yahoo.com - June 30 at 10:35 AM
businesswire.com logoBeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Business Wire
businesswire.com - June 30 at 4:55 AM
finance.yahoo.com logoBeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
finance.yahoo.com - June 30 at 4:55 AM
finance.yahoo.com logoDunad Therapeutics Appoints Industry Veteran Pearl Huang as Chief Executive Officer - Yahoo Finance
finance.yahoo.com - June 28 at 7:41 AM
nasdaq.com logoBiotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More - Nasdaq
nasdaq.com - June 22 at 3:27 PM
fool.com logoWhy Shares of BeiGene Popped Today - The Motley Fool
fool.com - June 22 at 10:27 AM
finance.yahoo.com logoBeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?
finance.yahoo.com - June 22 at 10:27 AM
finance.yahoo.com logoWhy Shares of BeiGene Popped Today
finance.yahoo.com - June 21 at 7:25 PM
businesswire.com logoBeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab - Business Wire
businesswire.com - June 21 at 7:16 AM
finance.yahoo.com logoBeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
finance.yahoo.com - June 21 at 7:16 AM
streetinsider.com logoBeiGene (BGNE) Announces PDUFA Extension for sNDA for BRUKINSA for the Treatment of CLL/SL - StreetInsider.com
streetinsider.com - June 13 at 8:45 PM
businesswire.com logoAsher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer - Business Wire
businesswire.com - June 13 at 10:44 AM
businesswire.com logoBeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets - Business Wire
businesswire.com - June 13 at 10:44 AM
finance.yahoo.com logoBeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
finance.yahoo.com - June 13 at 10:44 AM
finance.yahoo.com logoBeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
finance.yahoo.com - June 13 at 10:44 AM
finance.yahoo.com logoBeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress - Yahoo Finance
finance.yahoo.com - June 12 at 5:03 AM
seekingalpha.com logoBeiGene stock rises as tislelizumab gets approval in China for head/neck cancer subtype - Seeking Alpha
seekingalpha.com - June 10 at 5:09 PM
businesswire.com logoChina NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer - Business Wire
businesswire.com - June 10 at 8:36 AM
businesswire.com logoBeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress - Business Wire
businesswire.com - June 10 at 8:36 AM
finance.yahoo.com logoChina NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
finance.yahoo.com - June 10 at 8:36 AM
finance.yahoo.com logoBeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
finance.yahoo.com - June 10 at 8:36 AM
Get BeiGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:BGNE) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.